Braftovi (encorafenib) from Array BioPharma, along with Mektovi (binimetinib), is part of an oral BRAF/MEK inhibitor combination therapy used for patients with unresectable or metastatic melanoma (skin cancer that has spread) with a BRAF V600E or V600K gene mutation, as detected by an FDA-approved test. Both Braftovi and Mektovi are kinase inhibitors. Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma. Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 Mar 2019), Cerner Multum™ (updated 1 Mar 2019), Wolters Kluwer™ (updated 28 Feb 2019) and others. Refer to our editorial policy for content sources and attributions.